18 June 2020

Coloplast

Coloplast’s products are not quite dinner party conversation, as they help us when our plumbing stops working properly.

by John Royden

Head of Research

Group 10Created with Sketch.
Price
1042.00kr
Group 11Created with Sketch.
52 Week High-Low
1148.50kr—756.40kr
Page 1Created with Sketch.
Net Yield
1.72%
Group 12Created with Sketch.
Hist / Pros Per
57.00—48.74
Page 1Created with Sketch.
Equity Market Cap
213,062kr

They make stoma bags, which is what you get given if some of your intestines are surgically removed or temporarily out of order. Continence care is a large part of their sales as well as making the parts that surgeons use to fix the problem.

What is much more elegant and easy to talk about is their profit margins, which have been wonderfully constant up until now. Although this does not guarantee future success, the fact is that Coloplast are price setters. That’s what a constant profit margin as a percentage of sales implies. Would you quibble about the price of your stoma bag or would you try switching to test a new and cheaper product when your existing one works well? Probably not.

7% annual sales growth over the past decade is not to be sniffed at either. Success here is driven by the close relationship that Coloplast develop with the medical fraternity. Head to Copenhagen if you want to trade the shares, although you might wait until the capital markets day in September to get a better grip on the company’s future strategy in light of the dampening effect that Covid-19 has had on elective surgery.

Managing your wealth

Managing your wealth


Also in this issue

Capital Gains Tax (CGT) is a wide ranging and complex tax that in broad terms is levied on the increased value of certain possessions over the time that they have been held by their owner and is…

Autumn Issue Thirty Two